Page 3 - Adjuvant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SCHLIEREN, Switzerland, October 09, 2023--LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr

Adjuvant therapy, instead of just surgery alone, for early-stage non-small-cell lung cancer (NSCLC) after surgery incurs lower medical costs than surgery alone.

GSK's Arexvy vaccine for RSV can remain effective against a range of variants and produces strong antibody responses against distinct viral strains.

Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.